GlassScriptPhysician profile
Zelika Harouna Adamou
NPI 1629438403
$3,039.13
in general payments reported to CMS, 2019-2025
33 companies · $688 in 2025
The $688 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $286 · 2023: $776 · 2024: $1,165 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,265 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,265.05 |
| Education | $362.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $390.26 | 2021-2025 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $252.11 | 2022-2025 | Opdivo, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $243.91 | 2024-2025 | Tecvayli, Erleada, Rybrevant |
| Astellas Pharma US INC | $223.56 | 2023-2024 | Padcev |
| Genentech USA, INC. | $206.57 | 2022-2025 | Columvi, Polivy, Lunsumio |
| Seagen INC. | $184.00 | 2022-2023 | Adcetris, Tivdak |
| Merck Sharp & Dohme LLC | $128.15 | 2023-2025 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $121.99 | 2023-2024 | Ninlaro |
| Abbvie INC. | $113.16 | 2023-2025 | |
| Incyte Corporation | $87.74 | 2024-2025 | Zynyz, Monjuvi, Pemazyre |
| Celgene Corporation | $82.13 | 2024 | Reblozyl |
| Daiichi Sankyo INC. | $80.46 | 2024-2025 | Enhertu |
| Beigene USA, INC. | $74.64 | 2022-2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $74.62 | 2024-2025 | |
| Exelixis INC. | $69.62 | 2024-2025 | Cabometyx |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $68.12 | 2022-2023 | Lumakras, Nplate, Vectibix |
| Jazz Pharmaceuticals INC. | $64.90 | 2024-2025 | |
| Gilead Sciences, INC. | $58.24 | 2023-2024 | Trodelvy |
| Ferring Pharmaceuticals INC. | $51.29 | 2024-2025 | Adstiladrin |
| Novartis Pharmaceuticals Corporation | $51.04 | 2022-2025 | |
| Taiho Oncology, INC. | $46.92 | 2022-2023 | |
| Eisai INC. | $46.01 | 2022-2024 | |
| Acrotech Biopharma INC. | $44.37 | 2023-2025 | Beleodaq |
| Geron Corporation | $43.93 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $40.37 | 2024-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $33.55 | 2025 | Onivyde |
| Genmab U.S., INC. | $32.84 | 2024 | Epkinly |
| Array Biopharma INC | $23.32 | 2023 | Mektovi, Paxlovid, Lorbrena |
| Kyowa Kirin, INC. | $21.21 | 2024 | Poteligeo |
| Pfizer INC. | $21.16 | 2022 | |
| Adc Therapeutics America, INC. | $20.49 | 2025 | |
| Glaxosmithkline, LLC. | $20.45 | 2023 | Ojjaara |
| Morphosys, US INC. | $18.00 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zelika Harouna Adamou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.